- This event has passed.
Dr. Todd McAllister, “Stem Cell Therapies: the Hype, the Hope, and the Future” (June 7)
June 7, 2017 @ 12:30 pm - 1:30 pm
Executive Director, Amnion Foundation
Stem Cell Therapies: The Hype, The Hope, and the Future
Dr. Todd McAllister is the Executive Director at the Amnion Foundation, a public stem cell bank that is developing technology pioneered by Dr. Anthony Atala at Mass General Hospital in Boston. Amnion’s mission is to extend the successful model of public marrow and cord blood banking to provide immunologically matched stem cells with therapeutic capabilities beyond diseases of the blood.
Prior to Amnion, Dr. McAllister was co-founder and CEO of Cytograft, a cardiovascular regenerative medicine company that developed cell-based therapies to repair and rebuild diseased tissues without using synthetic biomaterials. Dr. McAllister’s was also the co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, Georgia, where he oversaw a broader range of cell-based cardiovascular repair technologies.
He has a B.S degree in Mechanical Engineering from the University of Washington, and a Ph.D. in Biomedical Engineering from the University of California, San Diego. With more than two decades of experience, Dr. McAllister is a well-known thought leader in the field of Regenerative Medicine. He has published his work in high impact journals including the New England Journal of Medicine, Lancet, and Nature Medicine. He is on the editorial board of the Journal of Biofabrication and on the Industry Committee for the Journal of Tissue Engineering. He is on the Executive Board for the International Cell Medicine Society, and has sat as a reviewer or external advisory board member for AFIRM, NIH, and NSF EPSCOR grants. He is well known for pioneering a novel, capital efficient business model that prioritizes capital efficiency and research focus, and has shared this knowledge on the advisory boards of several companies, including BioCardia, Lumen Therapeutics, Vault Stem Cells and others.